Reanalysis of Study After Removal of Participants in 1 Trial of Upadacitinib for Atopic Dermatitis

To the Editor On behalf of my coauthors, I write regarding a previously published article, “Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials,” which was published online first on April 12, 2023, and in the May 2023 issue of JAMA Dermatology. In this a rticle, we reported an analysis of 552 adolescents enrolled in 3 multicenter randomized clinical trials in more than 20 countries to assess the efficacy and safety of upadacitinib to treat moderate-to-severe atopic dermatitis in adolescents. We concluded that “upadacitinib was an effective treatme nt for adolescents with moderate-to-severe atopic dermatitis, with an acceptable safety profile.”(p526)
Source: JAMA Dermatology - Category: Dermatology Source Type: research